Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
By M. Parmar, Jonathan A. Ledermann, N. Colombo, B. Du, JF Delaloye, G. Kristensen, S. Wheeler, A. Swart, W. Qian, V. Torri and 4 more. The Lancet, 2003
1,166 citations recorded by the source corpus.
Subfields: Oncology, Reproductive Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/59bafbe408a2cdff08686476a2130cfb25c298d3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Reproductive Medicine
In Surgery
Citations in the corpus
- Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, background): “an improvement in response rate (54% vs 66%), time to disease progression (9 months vs 12 months), 1-year PFS (40% vs 50%), median survival (24 months vs 29 months), and 2-year survival (50% vs 57%) for the combination arm.(83) Some question the results of this study because the majority of patients”
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome (2013, neutral): “standard therapy randomization), BA06 in advanced bladder cancer [17], ICON4 in ovarian cancer [18] and OE02 in oesophageal cancer [19].”